Klotho在心力衰竭中作用的研究进展

doi:10.16352/j.issn.1001-6325.2023.06.0998

基础医学与临床 ›› 2023, Vol. 43 ›› Issue (6): 998-1002.doi: 10.16352/j.issn.1001-6325.2023.06.0998

Klotho在心力衰竭中作用的研究进展

柴亚如¹, 邓玉婷², 戴红艳², 管军^3*

1.潍坊医学院临床医学院,山东潍坊 261000;青岛市市立医院 2.保健心内科; 3.心内科,山东青岛 266000

收稿日期:2022-04-29 修回日期:2022-07-25 出版日期:2023-06-05 发布日期:2023-05-31
通讯作者: ^*guanjun@medmail.com.cn
基金资助:
青岛市科技惠民示范引导专项(21-1-4-rkjk-9-nsh);青岛市医疗卫生优秀学科带头人项目(青卫科教字[2019]9号)

Research progress on the role of Klotho in heart failure

CHAI Yaru¹, DENG Yuting², DAI Hongyan², GUAN Jun^3*

1. School of Clinical Medicine, Weifang Medical College, Weifang 261000; 2. Department of Healthcare Cardiology; 3. Department of Cardiology, Qingdao Municipal Hospital, Qingdao 266000, China

Received:2022-04-29 Revised:2022-07-25 Online:2023-06-05 Published:2023-05-31
Contact: ^*guanjun@medmail.com.cn

摘要/Abstract

摘要： Klotho是一种抗衰老蛋白,可分为全长跨膜型Klotho、可溶性Klotho 和分泌型Klotho 3种类型,其与氧化应激、炎性反应、心肌肥厚与纤维化、自噬、线粒体功能障碍等联系密切,参与抑制了心力衰竭的发生发展,有望为心力衰竭的治疗提供新的靶点和方向。

关键词: Klotho, 抗衰老蛋白, 心力衰竭

Abstract: Klotho is an anti-aging protein and can be divided into three types: full-length transmembrane Klotho, soluble Klotho and secreted Klotho. Many studies have shown that Klotho is closely related to oxidative stress, inflammatory response, myocardial hypertrophy, fibrosis, autophagy, and mitochondrial dysfunction. It is also involved in the occurrence and development of heart failure. It is expected to provide a new target and direction for the treatment of heart failure.

Key words: Klotho, anti-aging protein, heart failure

中图分类号:

R542

柴亚如, 邓玉婷, 戴红艳, 管军. Klotho在心力衰竭中作用的研究进展[J]. 基础医学与临床, 2023, 43(6): 998-1002.

CHAI Yaru, DENG Yuting, DAI Hongyan, GUAN Jun. Research progress on the role of Klotho in heart failure[J]. Basic & Clinical Medicine, 2023, 43(6): 998-1002.

参考文献 25

[1]	Olejnik A, Krzywonos-Zawadzka A, Banaszkiewicz M, et al. Klotho protein contributes to cardioprotection during ischaemia/reperfusion injury[J]. J Cell Mol Med, 2020, 24: 6448-6458.
[2]	Xu Z, Zheng S, Feng X, et al. Klotho gene improves oxidative stress injury after myocardial infarction[J] 2021, 21: 52. doi: 10.3892/etm.2020.9484.
[3]	Oishi H, Doi S, Nakashima A, et al. Klotho overexpres-sion protects against renal aging along with suppression of transforming growth factor-β1 signaling pathways[J]. Am J Physiol Renal Physiol, 2021, 321: F799-F811.
[4]	Akasaka-Manya K, Manya H, Nadanaka S, et al. Decreased ADAM17 expression in the lungs of α-Klotho reduced mouse[J]. J Biochem, 2020, 167: 483-493.
[5]	Wang X, Zhang G, Dasgupta S, et al. ATF4 protects the heart from failure by antagonizing oxidative stress[J]. Circ Res, 2022, 131: 91-105.
[6]	Song S, Si LY. Klotho ameliorated isoproterenol-induced pathological changes in cardiomyocytes via the regulation of oxidative stress[J]. Life Sci, 2015, 135: 118-123.
[7]	Zhu H, Gao Y, Zhu S, et al. Klotho improves cardiac function by suppressing reactive oxygen species (ROS) mediated apoptosis by modulating Mapks/Nrf2 signaling in doxorubicin-induced cardiotoxicity[J]. Med Sci Monit, 2017, 23: 5283-5293.
[8]	Chen K, Wang S, Sun QW, et al. Klotho deficiency causes heart aging via impairing the Nrf2-GR pathway[J]. Circ Res, 2021, 128: 492-507.
[9]	Hui H, Zhai Y, Ao L, et al. Klotho suppresses the inflammatory responses and ameliorates cardiac dysfunction in aging endotoxemic mice[J]. Oncotarget, 2017, 8: 15663-15676.
[10]	Lv J, Chen J, Wang M, et al. Klotho alleviates indoxyl sulfate-induced heart failure and kidney damage by promoting M2 macrophage polarization[J]. Aging (Albany NY), 2020, 12: 9139-9150.
[11]	Wang Y, Wang K, Bao Y, et al. The serum soluble Klotho alleviates cardiac aging and regulates M2a/M2c macrophage polarization via inhibiting TLR4/Myd88/NF-κB pathway[J]. Tissue Cell, 2022, 76: 101812. doi: 10.1016/j.tice.2022.101812.
[12]	Xie J, Cha SK, An SW, et al. Cardioprotection by Klotho through downregulation of TRPC6 channels in the mouse heart[J]. Nat Commun, 2012, 3: 1238. doi: 10.1038/ncomms2240.
[13]	Tang G, Shen Y, Gao P, et al. Klotho attenuates isoproterenol-induced hypertrophic response in H9C2 cells by activating Na(+)/K(+)-ATPase and inhibiting the reverse mode of Na(+)/Ca(2+)-exchanger[J]. In Vitro Cell Dev Biol Anim, 2018, 54: 250-256.
[14]	Chen WY. Soluble alpha-Klotho alleviates cardiac fibrosis without altering cardiomyocytes renewal[J]. Int J Mol Sci, 2020, 21: 2186. doi: 10.3390/ijms21062186.
[15]	Ding J, Tang Q, Luo B, et al. Klotho inhibits angiotensin II-induced cardiac hypertrophy, fibrosis, and dysfunction in mice through suppression of transforming growth factor-β1 signaling pathway[J].Eur J Pharmacol, 2019, 859: 172549. doi: 10.1016/j.ejphar.2019.172549.
[16]	Li JM, Chen FF, Li GH, et al. Soluble Klotho-integrin β1/ERK1/2 pathway ameliorates myocardial fibrosis in diabetic cardiomyopathy[J].FEBS J, 2021, 35: e21960. doi: 10.1096/fj.202100952R.
[17]	Suassuna PGA, Cherem PM, de Castro BB, et al. αKlotho attenuates cardiac hypertrophy and increases myocardial fibroblast growth factor 21 expression in uremic rats[J]. Exp Biol Med (Maywood), 2020, 245: 66-78.
[18]	Gao G, Chen W, Yan M, et al. Rapamycin regulates the balance between cardiomyocyte apoptosis and autophagy in chronic heart failure by inhibiting mTOR signaling[J]. Int J Mol Med, 2020, 45: 195-209.
[19]	Liao LZ, Chen ZC, Wang SS, et al. Klotho deficiency causes cardiac ageing by impairing autophagic and activating apoptotic activity[J]. Eur J Pharmacol, 2021, 911: 174559. doi: 10.1016/j.ejphar.2021.174559.
[20]	Chang YW, Song ZH, Chen CC. FAK regulates cardiomyocyte mitochondrial fission and function through Drp1[J]. FEBS J, 2022, 289: 1897-1910.
[21]	Zhuang X, Sun X, Zhou H, et al. Klotho attenuated Doxorubicin-induced cardiomyopathy by alleviating Dynamin-related protein 1-mediated mitochondrial dysfunc-tion[J]. Meth Ageing Dev, 2021, 195: 111442. doi: 10.1016/j.mad.2021.111442.
[22]	Zhu X, Lu X, Yin T, et al. Renal function mediates the association between Klotho and congestive heart failure among middle-aged and older individuals[J]Front Cardiovasc Med, 2022, 9: 802287. doi: 10.3389/fcvm.2022.802287.
[23]	张志敏, 苟丽沙, 马丽群, 等. 达格列净降低心力衰竭大鼠心肌内质网应激并缓解左室重构.[J]. 基础医学与临床, 2021, 41: 1742-1748.
[24]	Kale A, Sankrityayan H, Anders HJ, et al. Klotho: A possible mechanism of action of SGLT2 inhibitors preventing episodes of acute kidney injury and cardiorenal complications of diabetes[J]. Drug Discov Today, 2021, 26: 1963-1971.
[25]	Taneike M, Nishida M, Nakanishi K, et al. Alpha-Klotho is a novel predictor of treatment responsiveness in patients with heart failure[J]. Sci Rep, 2021, 11: 2058. doi: 10.1038/s41598-021-81517-9.

Klotho在心力衰竭中作用的研究进展

Research progress on the role of Klotho in heart failure

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 25

相关文章 15

编辑推荐

Metrics

本文评价

[1]	王英臣, 孙立群. 二肽基肽酶Ⅲ在治疗脓毒症中的应用进展[J]. 基础医学与临床, 2023, 43(1): 196-199.
[2]	樊佳赛, 杜艺菲, 许佳颖, 陈思臻, 高永桧, 任景怡. 基于中医证候和机器学习构建慢性心力衰竭中西医结合预后模型[J]. 基础医学与临床, 2022, 42(8): 1169-1175.
[3]	熊浩, 袁芳. 慢性肾脏病血管钙化机制的研究进展[J]. 基础医学与临床, 2022, 42(7): 1124-1128.
[4]	刘峰宇, 韩薇. 心肌细胞钙稳态失调在心力衰竭中作用的研究进展[J]. 基础医学与临床, 2022, 42(3): 502-506.
[5]	王放, 董哲, 孙艺红, 任景怡, 李菁, 周益锋, 郑金刚. 影响非缺血性心力衰竭患者心肌纤维化的因素分析[J]. 基础医学与临床, 2021, 41(3): 346-351.
[6]	张志敏, 苟丽沙, 马丽群, 任可, 路军, 魏星, 李慧杰, 周圣华. 达格列净降低心力衰竭大鼠心肌内质网应激并缓解左室重构[J]. 基础医学与临床, 2021, 41(12): 1742-1748.
[7]	刘颖娴, 宋彦君, 陈未, 林雪, 赖晋智, 黎婧怡, 吴炜. 非缺血性心力衰竭患者应用伊伐布雷定的有效性与安全性评价[J]. 基础医学与临床, 2021, 41(11): 1637-1642.
[8]	邱书娟孙秀菊李香玲郭振涛郭民. 银杏叶提取物减轻糖尿病大鼠肾缺血再灌注损伤[J]. , 2019, 39(12): 1729-1734.
[9]	胡欢李萍程晓曙. 线粒体融合-分裂与心力衰竭[J]. 基础医学与临床, 2018, 38(4): 553-556.
[10]	徐建平杨保卫. Ghrelin对心衰恶液质的治疗作用*[J]. 基础医学与临床, 2012, 32(1): 102-105.
[11]	李英莲李维善. 青海地区老年人心力衰竭患者血浆BNP水平变化与临床观察分析[J]. 基础医学与临床, 2010, 30(2): 205-205.
[12]	杨华沈珠军. 脂肪来源细胞在缺血性心脏病中的应用[J]. 基础医学与临床, 2010, 30(11): 1226-1229.
[13]	孔一慧曹荣元张莉刘玉冰李悦李为民. β3肾上腺素能受体激动剂和抑制剂对心衰大鼠心室MMP2和9表达的影响[J]. 基础医学与临床, 2010, 30(11): 1177-1183.
[14]	刘洪岩张金国谭洪勇. 慢性心力衰竭患者血浆APN水平与BNP、TNF-α、IR相关性[J]. 基础医学与临床, 2010, 30(10): 1098-1099.
[15]	王蕾王海鹏赵彩明韩莲花邹操刘志华蒋文平. 兔舒张性心衰和收缩性心衰模型建立及间质重构的比较[J]. 基础医学与临床, 2009, 29(12): 1244-1248.